|Page (1) of 1 - 09/12/17||email article||print page|
(September 12, 2017)
LONDON--(BUSINESS WIRE)--#MetabolicDisorders--The global sexual dysfunction drugs market is expected to grow at a CAGR of close to 3% during the forecast period, according to Technavios latest market research.
In this market research report, Technavio covers the market outlook and growth prospects of the global sexual dysfunction drugs market for 2017-2021. The market is further categorized into four therapy segments, including oral therapy, intracavernosal therapy, hormonal therapy, and transurethral therapy, of which oral therapy accounted for close to 74% of the market share in 2016.
According to Sapna Jha, a lead analyst at Technavio for cardiovascular and metabolic disorders research, ?The global sexual dysfunction drugs market offers both branded and generic drugs. This increases patient access to these medicines as the patient has a wide range of options to choose from, from low-cost drugs to high-cost drugs. The high cost of some of the branded drugs is due to high development cost and cost incurred during legal procedures to market those drugs.
Technavios research analysts segment the global sexual dysfunction drugs market into the following regions:
Looking for more information on this market? Request a free sample report
Technavios sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.
Sexual dysfunction drugs market in Americas
The sexual dysfunction drugs market in the Americas is expected to grow at a CAGR of over 2% during the forecast period owing to increasing cases of prostate cancer, Parkinson's disease, CVDs, and diabetes along with the adoption of sedentary lifestyles, which gradually causes the development of sexual dysfunctions, particularly erectile dysfunction (ED) among men aged 40 years and above.
The high performance of pioneer sexual dysfunction drugs offered by major US pharmaceutical companies such as Pfizer and Eli Lilly generates high revenue, making the country the largest contributor. The success of these drugs can be attributed to their efficacy, which has boosted their use among end-users. Furthermore, several pipeline drugs, which are under different stages of development and waiting for approval to be introduced into the market will fuel a huge demand in the market in the coming years.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.
Sexual dysfunction drugs market in EMEA
EMEA has experienced a high number of sexual dysfunction cases owing to factors such as sedentary lifestyles, sleep disorders, alcohol consumption, smoking, use of recreational drugs, obesity, depression, and CVDs. These factors are highly prevalent in major countries such as the UK, France, Germany, Italy, and Spain, which are the highest revenue contributors in the market.
Also, these countries have a high number of diabetes and prostate cancer cases that cause sexual dysfunction, which, in turn, increases demand for the drugs. Further, an increase in the number of men affected with Peyronie's disease is another major cause of sexual dysfunction in men. All these disease-related factors help in maintaining a steady demand for sexual dysfunction drugs, thus bolstering the market growth in this region.
Sexual dysfunction drugs market in APAC
Sexual dysfunction is common among older adults, resulting in decreased sexual functioning. The occurrence rate of ED is higher in older men as erection levels drop due to weakened penile muscles leading to an unsatisfactory sex life. This increases the demand for sexual dysfunction drugs, thereby bolstering the market growth.
APAC is witnessing an increasing trend of high disposable income among people, leading to the increased affordability of sexual dysfunction drugs, especially in countries such as China, India, and the Philippines. Also, the region is witnessing increasing cases of lifestyle diseases such as hypertension, CVDs, and diabetes that may gradually lead to sexual dysfunction.
?China and India offer huge opportunities for leading players in this market, as these countries account for a significantly large pool of under-served patients, who are being educated on sexual dysfunctions through awareness campaigns led by global bodies, thus ensuring an increase in demand for sexual dysfunction drugs in the coming years, says Sapna.
The top vendors in the global sexual dysfunction drugs market as highlighted in this market research analysis are:
- Eli Lilly
Browse Related Reports:
- Global Angina Pectoris Drugs Market 2017-2021
- Global Graft vs Host Disease (GVHD) Treatment Market 2017-2021
- Global Acute Ischemic Stroke Therapeutics Market 2017-2021
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavios report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at [email protected].
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Related Sites: DMN Newswire , HTN - Health Technology Net
Related Newsletter: Tutorial Finder , Review Seeker , DMN Newswire Newsletter